C4 THERAPEUTICS INC. - COMMON STOCK

C4 Therapeutics Reports Third Quarter 2022 Financial Results and Recent Business Highlights

03 نوفمبر 2022 07:00:02 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Receives Study May Proceed Letter from U.S. FDA to Initiate Phase 1/2 Clinical Trial of CFT1946, an Orally Bioavailable BiDAC™ Degrader, in BRAF-V600 Mutant Solid Cancers

29 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Present at Bank of America Securities Precision Oncology Conference 2022

26 سبتمبر 2022 07:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Second Quarter 2022 Financial Results and Recent Business Highlights

04 أغسطس 2022 08:00:03 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Appoints Experienced Clinical Development Leaders Laura Bessen, M.D. and Donna Grogan, M.D. to Board of Directors

02 أغسطس 2022 08:00:03 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces First Patient Dosed in Phase 1/2 Clinical Trial Evaluating CFT8634, an Orally Bioavailable BiDAC™ Degrader for the Treatment of Synovial Sarcoma and SMARCB1-null Tumors

16 مايو 2022 08:00:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports First Quarter 2022 Financial Results and Recent Business Highlights

05 مايو 2022 08:00:02 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Presents Clinical Data from Cohort A of the Ongoing Phase 1/2 Clinical Trial of CFT7455, a Novel IKZF1/3 Degrader

08 أبريل 2022 13:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Appoints Utpal Koppikar to Board of Directors

16 مارس 2022 16:05:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT8634 for the Treatment of Soft Tissue Sarcoma

09 مارس 2022 08:00:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Present at the American Association for Cancer Research (AACR) Annual Meeting 2022 

08 مارس 2022 16:30:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Full Year 2021 Financial Results and Recent Business Highlights

24 فبراير 2022 07:00:03 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces 2022 Key Milestones to Advance Targeted Protein Degradation Portfolio

10 يناير 2022 07:00:02 بحسب Nasdaq GlobeNewswire

C4 Therapeutics to Present at the 40th Annual J.P. Morgan Healthcare Conference

03 يناير 2022 07:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Added to NASDAQ Biotechnology Index

17 ديسمبر 2021 08:00:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Third Quarter 2021 Financial Results

10 نوفمبر 2021 16:01:01 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Reports Recent Business Highlights and Second Quarter 2021 Financial Results

11 أغسطس 2021 16:02:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces FDA Orphan Drug Designation for CFT7455 for the Treatment of Multiple Myeloma

11 أغسطس 2021 16:01:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Announces Closing of Public Offering and Exercise in Full of the Underwriters’ Option to Purchase Additional Shares

21 يونيو 2021 16:01:00 بحسب Nasdaq GlobeNewswire

C4 Therapeutics Presents Pre-clinical Data on CFT7455, a Novel IKZF1/3 Degrader for the Treatment of Hematologic Malignancies, at the 16th Annual International Conference on Malignant Lymphoma

21 يونيو 2021 08:00:01 بحسب Nasdaq GlobeNewswire